Artículos de revistas
Low Ten-eleven-translocation 2 (tet2) Transcript Level Is Independent Of Tet2 Mutation In Patients With Myeloid Neoplasms
Registro en:
Diagnostic Pathology. BIOMED CENTRAL LTD, n. 11, n. 28, p. .
1746-1596
WOS:000372423800001
10.1186/s13000-016-0476-4
Autor
Scopim-Ribeiro
R; Machado-Neto
JA; Campos
PD; Niemann
FS; Lorand-Metze
I; Costa
FF; Saad
STO; Traina
F
Institución
Resumen
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) New sequencing technologies have enabled the identification of mutations in Ten-eleven-translocation 2 (TET2), an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) in myeloid neoplasms. We have recently identified reduced TET2 mRNA expression in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), which is associated with a poor overall survival in MDS. We herein aimed to investigate TET2 mutations and their impact on TET2 expression in a cohort of patients with myeloid neoplasms, including MDS and AML patients. Findings: TET2 mutations were observed in 8 out of 19 patients (42 %) with myeloid neoplasms. The TET2 expression profile was similar between in wild type and in TET2 mutated patients. Conclusion: Our results suggest that TET2 expression is reduced in MDS/AML patients, independently of mutational status. 11
Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [610021/2009-5, 2011/51959-0, 2011/15905-3, 2012/09982-8] Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)